OPINION/HYPOTHESIS {#s1}
==================

Exposure to environmental factors plays a key role in human health. However, the impact of biological and chemical particles in the environment on human health is poorly understood. High-throughput sequencing of DNA is a powerful approach to identify fungal pathogens in environmental sources ([@B1]). Fungi represent a significant fraction of microorganisms identified in environmental metagenomics data sets.

*Pneumocystis* species are opportunistic fungi that exclusively infect mammals, yet each species displays a high level of host specificity. As extracellular parasites, *Pneumocystis* organisms have been found almost exclusively in the alveolar space in the lungs of mammals ([@B2]). These organisms cause severe pneumonia in immunocompromised individuals and are also able to asymptomatically infect healthy individuals. In humans, *Pneumocystis* pneumonia (PCP) is caused by Pneumocystis jirovecii and is a serious public health issue with a high mortality rate if untreated ([@B3]). Renal transplant and untreated HIV-infected patients have an exceptionally high risk of developing PCP.

The *Pneumocystis* life cycle is thought to alternate primarily between vegetative active trophic forms and metabolically inert ascii (cysts) ([@B4]). Trophic forms are believed to replicate by asexual reproduction via binary fission, and ascii, by sexual reproduction ([@B5]). *Pneumocystis* organisms require a living host to survive and remain unculturable *in vitro*. The parasitic nature of their relationship with mammalian hosts is reflected in their genomes, which lack many genes involved in *de novo* biosynthesis of essential nutrients and, instead, encode mechanisms to scavenge nutrients from the host (we refer interested readers to references [@B2] and [@B6] and the references therein). Their metabolic machinery seems ill-equipped to survive outside their hosts; that is, viable trophic forms are unlikely to be found in the environment.

*Pneumocystis* infection is mediated by transmission of ascii ([@B7]) between an infected host and a susceptible host ([@B8], [@B9]). Although *Pneumocystis* DNA has been reported to be in the environment (see reference [@B2]), it remains unclear if and for how long a *Pneumocystis* cell can remain viable outside its host.

The epidemiology of *Pneumocystis* infection is poorly understood and has been almost exclusively studied in humans in the context of drug resistance or outbreaks. Most of the studies utilize a multilocus sequencing approach targeting a few mitochondrial and nuclear genes. The structure of *P. jirovecii* populations is ambiguous. Some studies have reported a strong local population structure mediated by clusters of infected patients ([@B10]); however, this is not supported by other studies ([@B11]). These conflicting results could be explained by the presence of viable ascii in the environment over extended periods of time. If *Pneumocystis* ascii are able to survive in the environment, spores could disperse over large geographical distances. In such a scenario, individuals would be constantly infected with new strains, therefore creating highly heterogeneous populations, which would be consistent with the observed high prevalence of coinfections with multiple *P. jirovecii* strains ([@B11], [@B12]). *Pneumocystis* ascii share similarities with other long-distance fungal dispersers, for example, the presence of glucans in the cell wall, which likely promote survival in a harsh environment. The scenario of a long-distance dispersal of *Pneumocystis* ascii has not been explored to date. If *Pneumocystis* ascii are ubiquitous, then humans should simultaneously be exposed to different *Pneumocystis* species, but only *P. jirovecii* cells would be able to replicate. Under this model, we should expect a widespread coexistence of ascii from different *Pneumocystis* species in the environment.

Although patients with PCP have high organism burdens which likely facilitate transmission, healthy carriers also potentially play a role. The transmission of *Pneumocystis* through immunocompetent individuals has been demonstrated in animal models ([@B13]). In this situation, *Pneumocystis* organisms are able to actively infect new hosts and complete their life cycle with the ability to release newly formed ascii before the host immune system clears the infection. Assuming that recurrent infections are frequent, healthy individuals would be the primary source of ascii. In that case, we should expect a high density of *P. jirovecii* ascii in the vicinity of humans, irrespective of the presence of immunocompromised individuals.

A recent study published in *Cell* ([@B14]) exploring the dynamics of the human environmental exposome provided an opportunity to investigate our hypotheses. The authors collected and analyzed metagenomic sequences from air filter devices attached to 15 self-declared healthy adults. These individuals were followed for up to 890 days over 66 different geographical locations. The data set is available as 594 SRA files in the NCBI SRA database (∼5 TB of raw data). We also utilized data from two additional metagenomics studies from surface swabs across New York City (NYC) subway systems, the Gowanus Canal, and public parks (1,573 SRA files) ([@B15]) and the collection of 63 uncultured hospital air samples collected over a 6-month period (6,888 SRA files) ([@B16]). Here, we show clear evidence of *P. jirovecii*, but no other *Pneumocystis* species, in air filters from 4 out of 15 individuals in the human exposome study ([@B14]), whereas no evidence of *Pneumocystis* was identified in the other two studies, possibly because the sampling methods were not suitable for *Pneumocystis* detection. The significance of this finding is discussed in the context of epidemiology and host species specificity.

SUMMARY OF PERSONAL ENVIRONMENTAL EXPOSURE SAMPLE COLLECTION {#s2}
============================================================

We reproduce here a summary of the sampling methodology of the original exposome study ([@B14]). All 15 participants recruited lived in the northern California Greater Bay Area, and some traveled to other locations. All participants were age 18 or older and self-reported as healthy. A MicroPEM v3.2 personal exposure monitor (RTI International, Research Triangle Park, NC, USA) was modified and used to simultaneously collect biotic and abiotic samples of personal aerosol exposure for the period of August 2014 to January 2017. Before sampling and data collection, a 3.0-mm pore-size polytetrafluoroethylene (PTFE) 25-mm Teflon filter (Pall Corporation, Port Washington, NY, USA) or a 0.8-mm pore-size polyethersulfone (PES) 25-mm filter (Sterlitech, Kent, WA, USA) was placed in MicroPEM filter cassettes to collect aerosol particulates for biotics extraction. Participants were instructed to either carry the monitor on their arm or place the monitor near them within a 2-m radius at all times during the sampling period. At the end of the sampling and monitoring period, filters and cartridges were removed from the monitor and stored at --80°C until analysis. None of the individuals were health care workers or involved in animal models of PCP.

Detection of *Pneumocystis* in air metagenomes. {#s2.1}
-----------------------------------------------

Raw data were download from NCBI (last accessed June 2019) and mapped to the following genomes using Bowtie 2 ([@B17]): nuclear genomes of three *P. jirovecii* strains (RU7 \[[@B18]\], SE8 \[[@B19]\], and SE2178 \[[@B20]\]); single strains of Pneumocystis sp. *macacae* that infect macaques (O. H. Cissé, L. Ma, J. Brenchley, and J. A. Kovacs, unpublished), Pneumocystis carinii that infect rats ([@B18]), and Pneumocystis murina that infect mice ([@B18]); and mitochondrial genomes of *P. jirovecii*, P. carinii, and P. murina ([@B21]).

Mapped reads were assembled using metaSPades ([@B22]). Small-size contigs (\<500 nucleotides) and/or those with a high GC content (\>50%; because *Pneumocystis* genomes have a GC content of ∼30%) were separated. Analysis of small-size and/or high-GC content contigs indicated that they were heavily enriched in ambiguous ribosomal DNA (rDNA) sequences and low complexity repeats, the vast majority of which could not be reliably categorized. The remaining contigs were aligned to the reference genome sequences using BLAT ([@B23]) with a minimum nucleotide alignment score of 200 as the threshold. Ribosomal DNA and low-complexity sequences were excluded because of their high rates of false positivity. A total of 1,711 contigs were retained for further investigation. Contigs were annotated with AUGUSTUS ([@B24]) using *Pneumocystis* built-in models ([@B25]). Orthology was inferred using the reciprocal best BLASTn hit ([@B26]) with an E value of 10^−10^ as the cutoff. For each orthologous group, sequence orientations were assessed using Revseq from the EMBOSS package ([@B27]), aligned using MUSCLE ([@B28]), and visually inspected for alignment inconsistencies using AliView ([@B29]). Maximum likelihood phylogenies were inferred using RAxML-NG ([@B30]) with 100 replicates as support values. Pairwise nucleotide identities were calculated using Water from EMBOSS.

Variant calling was performed by aligning retrieved reads from the NCBI SRA to *P. jirovecii* genome assembly strain RU7 (NCBI accession number [GCF_001477535.1](https://www.ncbi.nlm.nih.gov/assembly/GCF_001477535.1/)) using the Burrows-Wheeler Aligner MEM algorithm (BWA-MEM) ([@B31]). To assess the levels of different mammal DNAs, Illumina raw reads were aligned using BWA-MEM to the following genomes: NCBI accession numbers [GCF_000001405.39](https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.39/) (human), [GCF_000002285.3](https://www.ncbi.nlm.nih.gov/assembly/GCF_000002285.3/) (dog), [GCF_000181335.3](https://www.ncbi.nlm.nih.gov/assembly/GCF_000181335.3/) (cat), [GCF_000151735.1](https://www.ncbi.nlm.nih.gov/assembly/GCF_000151735.1/) (guinea pig), [GCF_000001895.5](https://www.ncbi.nlm.nih.gov/assembly/GCF_000001895.5/) (rat), and [GCF_000001635.25](https://www.ncbi.nlm.nih.gov/assembly/GCF_000001635.25/) (mouse). Alignment files (BAM) were filtered and sorted with SAMtools ([@B32]) using "-f 3 -F 4 -F 8 -F 256 -F 2048 -q 30" to keep high-quality reads (mapping quality ≥ 30 and properly paired). Duplicates were marked using Picard MarkDuplicates v2.1.1 (<http://broadinstitute.github.io/picard>). Per base genome, sequencing depths (coverage breaths) were computed from BAM files using BEDTools ([@B33]) with the "genomeCoverageBed" option. Variants were identified using FreeBayes v1.3.1-dirty ([@B34]) with the parameters "--ploidy 1" and vcffilter "-f QUAL \> 30." Variant positions were annotated using BEDTools with the "annotate" option. Analyses were conducted with Perl v5.22.0 scripts (<http://www.perl.org/>) using Bioperl v1.7.6 ([@B35]). Statistical analyses were conducted in R v3.3.2 ([@B36]). Hierarchical clustering was done using pheatmap v1.0.12 ([@B37]). Phylogenetic trees were visualized using FigTree v1.4.4 ([@B38]). Pipelines were written using Snakemake ([@B39]). All analyses, including alignments, accessions, and custom scripts are available at <https://github.com/ocisse/Exposome>.

*Pneumocystis* organisms are present in the human exposome. {#s2.2}
-----------------------------------------------------------

We identified *Pneumocystis* reads in 24 of the 594 SRA files provided by the human exposome study ([@B14]). These 24 SRA files represent air filters from 4 of 15 individuals ([Table 1](#tab1){ref-type="table"}). We found no conclusive evidence of *Pneumocystis* presence in the metagenomic data sets from the surface swabs of the NYC subway system ([@B15]) or air samples from hospitals ([@B16]). The latter study used filters to capture particles between 0.1 and 10 μm in size, which should capture *Pneumocystis* ascii if they are present. However, the depth of sequencing appears lower than for those of other data sets. Only data from the human exposome study ([@B14]) were used for subsequent analyses.

###### 

Proportion of *Pneumocystis* and selected mammal DNA in air filter metagenomes

  SRA accession no.                                           Source[^*a*^](#ngtab1.1){ref-type="table-fn"}   Date[^*b*^](#ngtab1.2){ref-type="table-fn"} (M/D/Y)   No. of paired-end reads   Proportion of genome bases covered by at least two sequencing reads (2× coverage) (%)[^*c*^](#ngtab1.3){ref-type="table-fn"}   Geographic location                                             
  ----------------------------------------------------------- ----------------------------------------------- ----------------------------------------------------- ------------------------- ------------------------------------------------------------------------------------------------------------------------------ --------------------- ------ -------- ------- -------- -------- -----------------------------
  [SRR6399753](https://www.ncbi.nlm.nih.gov/sra/SRR6399753)   P1                                              10/29/14                                              46,823,961                0.16                                                                                                                           0.05                  0.02   0.02     0.01    0.02     0.01     Cambridge, MA, USA
  [SRR6399562](https://www.ncbi.nlm.nih.gov/sra/SRR6399562)   P1                                              11/6/14                                               81,370,159                0.77                                                                                                                           0.09                  0.05   0.06     0.04    0.05     0.01     Bethesda, MD, USA
  [SRR6399671](https://www.ncbi.nlm.nih.gov/sra/SRR6399671)   P1                                              2/1/15                                                57,429,806                0.51                                                                                                                           0.04                  0.03   0.02     0.01    0.01     0.01     San Francisco, CA, USA
  [SRR6399870](https://www.ncbi.nlm.nih.gov/sra/SRR6399870)   P1                                              8/2/15                                                49,422,187                0.37                                                                                                                           0.06                  0.04   0.03     0.02    0.01     0.01     Palo Alto, CA, USA
  [SRR6399877](https://www.ncbi.nlm.nih.gov/sra/SRR6399877)   P1                                              8/11/15                                               64,558,662                0.67                                                                                                                           0.10                  0.08   0.08     0.07    0.06     0.05     Palo Alto, CA, USA
  [SRR6399596](https://www.ncbi.nlm.nih.gov/sra/SRR6399596)   P1                                              10/3/15                                               66,441,164                0.09                                                                                                                           0.06                  0.02   0.02     0.01    0.01     0.01     Lexington, KY, USA
  [SRR6399808](https://www.ncbi.nlm.nih.gov/sra/SRR6399808)   P1                                              12/3/15                                               45,397,952                0.18                                                                                                                           0.03                  0.01   0.01     0.007   \<0.01   \<0.01   Bethesda, MD, USA
  [SRR6399953](https://www.ncbi.nlm.nih.gov/sra/SRR6399953)   P1                                              1/2/16                                                94,139,119                2.53                                                                                                                           1.25                  0.40   0.37     0.18    0.19     0.16     West Hartford, CT, USA
  [SRR6399569](https://www.ncbi.nlm.nih.gov/sra/SRR6399569)   P1                                              1/7/16                                                87,515,965                1.04                                                                                                                           0.16                  0.07   0.07     0.06    0.06     0.05     San Diego, CA, USA
  [SRR6399527](https://www.ncbi.nlm.nih.gov/sra/SRR6399527)   P1                                              1/10/16                                               68,493,408                0.28                                                                                                                           0.04                  0.02   0.02     0.01    0.01     \<0.01   Los Angeles, CA, USA
  [SRR6399888](https://www.ncbi.nlm.nih.gov/sra/SRR6399888)   P1                                              4/6/16                                                71,048,240                0.58                                                                                                                           0.61                  0.24   0.24     0.07    0.04     0.04     Pottstown, PA, USA
  [SRR6399614](https://www.ncbi.nlm.nih.gov/sra/SRR6399614)   P1                                              5/12/16                                               56,634,040                0.42                                                                                                                           0.07                  0.01   0.01     0.03    0.04     0.02     Cold Spring Harbor, NY, USA
  [SRR6399464](https://www.ncbi.nlm.nih.gov/sra/SRR6399464)   P1                                              6/17/16                                               75,614,307                0.51                                                                                                                           0.08                  0.06   0.06     0.04    0.05     0.04     San Diego, CA, USA
  [SRR6399789](https://www.ncbi.nlm.nih.gov/sra/SRR6399789)   P1                                              11/28/16                                              61,447,835                1.59                                                                                                                           0.37                  0.11   0.11     0.09    0.07     0.08     Palo Alto, CA, USA
  [SRR6399684](https://www.ncbi.nlm.nih.gov/sra/SRR6399684)   P1                                              12/5/16                                               69,122,523                1.68                                                                                                                           0.23                  0.30   0.23     0.09    0.11     0.12     Palo Alto, CA, USA
  [SRR6399520](https://www.ncbi.nlm.nih.gov/sra/SRR6399520)   P1                                              1/2/17                                                66,800,060                0.65                                                                                                                           0.19                  0.14   0.10     0.04    0.05     0.04     West Hartford, CT, USA
  [SRR6399939](https://www.ncbi.nlm.nih.gov/sra/SRR6399939)   P3                                              3/7/16                                                51,995,194                2.00                                                                                                                           0.61                  0.08   0.08     0.05    0.04     0.04     Redwood City, CA, USA
  [SRR6399879](https://www.ncbi.nlm.nih.gov/sra/SRR6399879)   P3                                              3/29/16                                               82,285,688                1.13                                                                                                                           1.45                  0.23   0.24     0.30    0.13     0.12     San Mateo, CA, USA
  [SRR6399803](https://www.ncbi.nlm.nih.gov/sra/SRR6399803)   P3                                              11/28/16                                              67,067,766                1.07                                                                                                                           0.42                  0.12   0.11     0.20    0.12     0.09     San Mateo, CA, USA
  [SRR6399681](https://www.ncbi.nlm.nih.gov/sra/SRR6399681)   P3                                              12/5/16                                               56,853,387                0.56                                                                                                                           0.18                  0.06   0.11     0.09    0.12     0.04     San Mateo, CA, USA
  [SRR6399685](https://www.ncbi.nlm.nih.gov/sra/SRR6399685)   P3                                              12/11/16                                              62,867,255                0.61                                                                                                                           0.11                  0.09   \<0.01   0.18    0.08     0.07     New York, NY, USA
  [SRR6399802](https://www.ncbi.nlm.nih.gov/sra/SRR6399802)   P5                                              11/27/16                                              54,602,220                0.31                                                                                                                           0.13                  0.04   0.04     0.03    0.03     0.03     Cupertino, CA, USA
  [SRR6399682](https://www.ncbi.nlm.nih.gov/sra/SRR6399682)   P5                                              12/6/16                                               62,121,563                0.53                                                                                                                           0.09                  0.06   0.05     0.12    0.04     0.04     Cupertino, CA, USA
  [SRR6399512](https://www.ncbi.nlm.nih.gov/sra/SRR6399512)   P8                                              2/23/16                                               59,583,085                0.35                                                                                                                           0.20                  0.04   0.04     0.02    0.02     0.01     Palo Alto, CA, USA

![](mBio.03138-19-t0001)

Identification codes of the tracked individuals.

Month/day/year.

Genome sizes: *P. jirovecii*, 8.3 Mb; human, 3.2 Gb; dog, 2.4 Gb; cat, 2.5 Gb; guinea pig, 2.7 Gb; rat, 2.8 Gb; mouse, 2.8 Gb.

Humans seem to be selectively exposed to Pneumocystis jirovecii. {#s2.3}
----------------------------------------------------------------

The *de novo* assembly of *Pneumocystis* reads retrieved from 24 SRA files yielded 45 contigs larger than 500 nucleotides ([Table 1](#tab1){ref-type="table"}). Maximum likelihood phylogeny and pairwise alignment identity scores for 37 of 45 contigs with their one-to-one ortholog unambiguously identified all contigs as being from *P. jirovecii* and clearly distinct from all other *Pneumocystis* species analyzed ([Fig. 1 A](#fig1){ref-type="fig"} and [B](#fig1){ref-type="fig"}). The remaining eight contigs, which lack homologs that are present in other *Pneumocystis* species, were clearly identified as *P. jirovecii* based on pairwise alignments. This was a somewhat surprising finding given that multiple *Pneumocystis* species are distributed in the ambient air surrounding mammals. While *Pneumocystis* species show a strict host species specificity for productive infection, air sampling does not depend on replication of the organism but should randomly sample the proximal ambient air. Given that *Pneumocystis* species appear unable to replicate outside the mammalian host, including in air filters, the only source of aerosolized organisms appears to be an infected host of the same species. While *Pneumocystis* can cause pneumonia in immunosuppressed hosts, it can also lead to subclinical infection or colonization in immunocompetent hosts, and sampling of, e.g., wild rodents demonstrates the presence of *Pneumocystis* DNA in ∼30 to 90% of animals ([@B40], [@B41]). None of the individuals involved in the study were reported to have an immunodeficiency, although we cannot rule out undisclosed medical conditions or contact with an infected immunocompromised patient. We have information that at least some individuals included in the study had close contact with animals such as pets, laboratory animals, or zoo animals (see <https://www.technologynetworks.com/proteomics/news/exposing-the-exposome-309789>).

![Evidence of *Pneumocystis* DNA in air metagenomes. (A) Pairwise nucleotide identity heatmap of 37 of 45 contigs. Only contigs for which a 1-to-1 ortholog could be established were used. Blank spaces in the heatmap represent a lack of an identifiable ortholog. These missing orthologs likely represent an incomplete genome or annotation rather than real biological gene loss. (B) Maximum likelihood phylogeny of a representative contig encoding the 3-oxoacyl-\[acyl-carrier-protein\] synthase (arrow). The contig was recovered from the NCBI SRA accession number [SRR6399569](https://www.ncbi.nlm.nih.gov/sra/SRR6399569). Bootstrap values of 100 replicates are presented on the tree nodes. Sequences are labeled with the following species identifiers: PJIR, Pneumocystis jirovecii; PMAC, *Pneumocystis* sp. *macacae*; PCAR, P. carinii; PMUR, P. murina. *P. jirovecii* sequences are boxed. (C) Single nucleotide polymorphisms (SNP) were identified from the alignments of raw reads from each SRA file to *P. jirovecii* reference genome assembly strain RU7. The heatmap shows the variant calling results for 1,852 genomic positions encoded as follows: black, presence of a SNP; gray, region covered by at least two sequencing reads with the allele as the reference genome; white, absence of coverage. Each row represents a unique SNP, and each column represents the 15 samples with detectable *Pneumocystis* sequences. Collection dates (month/year) are presented at the bottom of the figure.](mBio.03138-19-f0001){#fig1}

Dog and cats cannot be infected by *P. jirovecii*, but they can be infected by genetically distinct *Pneumocystis* species. *Pneumocystis* pneumonia is rare in dogs ([@B42]), although severe cases with development of spontaneous pneumomediastinum have been reported ([@B43], [@B44]). The agent Pneumocystis sp. *canis* is phylogenetically related but clearly distinct from *P. jirovecii* and other *Pneumocystis* species ([@B45]). The *Pneumocystis* species that infects cats is referred as *Pneumocystis* sp. *catus* and constitutes another distinct species ([@B46]). While spontaneous PCP has not been observed in cats, PCP is frequently found in feline immunodeficiency virus-infected ([@B47]) or corticoid-treated cats ([@B48]). The low occurrence of PCP in healthy dogs and cats suggests that their immune system clears or maintains *Pneumocystis* organism loads at a low level. Therefore, healthy animals are expected to be colonized or infected subclinically, similar to healthy humans. Given that the phylogenetic placement of both *Pneumocystis* sp. *canis* and *Pneumocystis* sp. *catus* is known and that the nucleotide divergence of *P. jirovecii* with these two species exceeds 16% ([@B46], [@B49]), our unbiased approach would have recovered sequences from these species if present, even in the absence of complete genome sequences. If present, *Pneumocystis* sp. *canis* and *Pneumocystis* sp. *catus* sequences would be easy to identify in a phylogenetic tree because they will not cluster with any of the species used here and, instead, have their own branches located between primate *Pneumocystis* species (*P. jirovecii* and *Pneumocystis* sp. *macacae*) and rodent *Pneumocystis* species (P. carinii and P. murina).

Unlike other fungi that can replicate in the environment (e.g., in soil) and for which even a single organism has the potential to replicate wherever it lands, a *Pneumocystis* cyst, the infective form of the organism, must be inhaled and presumably deposited into the alveoli to initiate productive infection. We found high levels of mammal DNA, including that of humans and animals, in the air metagenomes where *P. jirovecii* DNA was detected ([Table 1](#tab1){ref-type="table"}), which suggest that other *Pneumocystis* species would have been detected if present. The absence of non-*P. jirovecii* sequences in the human exposome suggests that *Pneumocystis* cysts can travel for only a limited range from the infected host, or if they travel long distances, the likelihood of being inhaled (or sampled in the current study) diminishes very rapidly. Thus, efficient transmission likely requires close proximity to an infected host ([@B50]). The fact that none of the filters contained other species of *Pneumocystis* strengthens the likelihood of a selective exposure of humans to *P. jirovecii*, though the limited number of species included in our database represents a potential caveat.

Participants were instructed to either carry the monitor on their arm or place the monitor near them within a 2-m radius at all times during the sampling period. Assuming that the filter was worn on the upper arm at all times, it is unlikely that this would create a significant barrier to the deposition of *Pneumocystis* from four-legged mammals, particularly from smaller animals. The reason is that experimental data from animal models suggest that *Pneumocystis* ascii remain in suspension in the ambient air. Noninfected rats acquired P. carinii and developed PCP when exposed to the exhaled air from infected rats ([@B51], [@B52]). In addition, *Pneumocystis* ascii from different species are of similar size, 3.5 to 8 μm (reviewed in reference [@B53]), which suggests similar ascii dispersion capabilities, although interspecies differences cannot be ruled out. At the time of this writing, we are not aware of any study that has compared ascii diffusion properties in multiple *Pneumocystis* species. Another confounding factor is that *P. jirovecii* populations would be expected to outnumber those of other *Pneumocystis* populations in human-dense areas. This would allow a higher recovery yield for *P. jirovecii* versus other *Pneumocystis* species but should not influence the recovery of other species.

To investigate whether the air filters were seeded with a single strain or multiple strains of *P. jirovecii*, we aligned raw reads to *P. jirovecii* reference genome assembly strain RU7 (19) and identified single nucleotide polymorphisms (SNP). We filtered out singletons and analyzed 1,852 SNP positions. SNP profiles from different air filters appear to be heterogeneous, which indicates a wide dispersion of samples from individuals ([Fig. 1C](#fig1){ref-type="fig"}) and could reflect the differences in sampling times or exposure to different infected hosts. In addition, 115 of 1,852 positions overlap genomic regions encoding highly polymorphic major surface glycoproteins (Msg), which would presumably further enhance the genetic heterogenicity among isolates. In fact, the hypervariability of *msg* genes has been extensively used to study strain variation of *P. jirovecii* ([@B54], [@B55]). Overall, the source of the *Pneumocystis* that was sampled cannot be determined, but it presumably was either the volunteer or someone else in close proximity, which would be consistent with the dynamics of *Pneumocystis* air shedding ([@B8], [@B56]). Whatever the source, the frequent detection of *Pneumocystis* DNA suggests frequent shedding of organisms, which is consistent with serologic data suggesting that most humans have been infected by *Pneumocystis* at an early age ([@B57], [@B58]).

Concluding remarks. {#s2.4}
-------------------

Our observations highlight the potential impact of metagenomics to improve our understanding of fungal pathogen transmission and epidemiology. Our results support a short-range transmission model and suggest that close-range exposure to infected hosts may play a significant role in transmission of *Pneumocystis*. Analyses of publicly available metagenomic data sets provide new opportunities for modeling and exploring human exposure to airborne infectious pathogens.
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